Omega-3 Fatty Acids and Fish Oil: study protocols
14 study groups took Omega-3 Fatty Acids together with Fish Oil. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Omega-3 Fatty Acids
14 study groups in 11 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 g to 5 g, 36% of 14 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 3 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 4 |
| 1 g to 2.5 g | 2 |
| 2.5 g to 5 g | 5 |
Dose per serving from research: Fish Oil
12 study groups in 9 studies say how much Fish Oil participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 50% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg or less | 1 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 6 |
| 1 g to 2.5 g | 1 |
| 2.5 g to 5 g | 4 |
Commonly used together
5 of 14 study groups took Omega-3 Fatty Acids and Fish Oil with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Docosahexaenoic Acid | 4 |
14 study groups
| Study | ||||
|---|---|---|---|---|
| Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL 2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial | 840 mg | 1 g | 5 years | 12,933 |
| Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial 2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30 | 2.7 g | 4 g | — | 266 |
| Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease 1996 · fish-oil group · Patients with Crohn's disease in remission at high risk of relapse; age and sex not specified | 2.7 g | — | 1 year | 39 |
| Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration 1992 · fish oil · Healthy Danish women in week 30 of pregnancy | 2.7 g | — | — | — |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 680 mg | 1 g | 8 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 680 mg | 1 g | 8 weeks | 10 |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 700 mg | 700 mg | 8 weeks | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 1.8 g | 1.8 g | 8 weeks | — |
| Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease 1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated | 3.4 g | 4 g | 39 weeks | 260 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.86 g | 3.36 g | 1 year | 147 |